博雅生物(300294) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥624,118,627.05, representing a 2.38% increase compared to ¥609,594,359.83 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥100,736,164.66, up 5.04% from ¥95,900,464.56 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥98,876,255.69, reflecting a 12.38% increase from ¥87,981,685.60 in the previous year[8]. - Basic and diluted earnings per share for Q1 2021 were both ¥0.24, a 4.35% increase from ¥0.23 in the previous year[8]. - Operating profit reached ¥122,974,479.86, reflecting a growth of 5.96% compared to the same period last year[28]. - The blood products business generated total operating revenue of ¥283,471,117.56, a year-on-year increase of 17.10%[28]. - The net profit from the blood products business was ¥84,430,633.20, representing a growth of 43.19% year-over-year[28]. - Net profit for the current period was ¥103,957,040.08, compared to ¥99,887,304.66 in the previous period, reflecting a growth of approximately 2.1%[79]. - Total operating revenue for the current period reached ¥624,118,627.05, an increase from ¥609,594,359.83 in the previous period[74]. Cash Flow and Assets - The net cash flow from operating activities increased significantly by 127.42%, reaching ¥159,306,575.70 compared to ¥70,048,130.64 in the same quarter last year[8]. - As of March 31, 2021, the company's cash and cash equivalents amounted to 668,822,235.13 RMB, a decrease from 753,894,253.78 RMB at the end of 2020[56]. - The total current assets decreased to 2,760,475,116.63 RMB from 2,927,663,474.49 RMB at the end of 2020[56]. - The company's total liabilities decreased from ¥966,078,096.11 to ¥708,746,713.24, a decrease of about 26.5%[62]. - Total assets at the end of the reporting period were ¥5,005,101,156.91, down 2.97% from ¥5,158,535,284.56 at the end of the previous year[8]. - Cash and cash equivalents decreased from ¥645,846,795.60 to ¥386,343,704.73, a drop of about 40%[66]. - The ending cash and cash equivalents balance decreased to 386,343,704.73 CNY from 457,940,294.04 CNY, a decline of 15.5%[97]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,886[11]. - The largest shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., held 29.17% of the shares, amounting to 126,381,618 shares[12]. - Net assets attributable to shareholders increased by 2.45% to ¥4,208,580,030.35 from ¥4,107,903,650.55 at the end of the previous year[8]. Regulatory and Management Changes - The company has undergone a change in its board of directors and management team, with new appointments made on February 4, 2021[37]. - The company is subject to regulatory measures due to previous financial misconduct, and corrective actions have been taken[34]. - The company received a notice from the Shenzhen Stock Exchange regarding the suspension of the review for the issuance of A-shares to specific targets[33]. - The company is awaiting approval from relevant authorities for the issuance of shares related to the change in controlling shareholder[33]. Research and Development - R&D expenses decreased by 54.86% to ¥8,165,544.65 compared to the previous year[25]. - Research and development expenses decreased significantly to ¥2,611,824.06, down 76.3% from ¥11,043,867.32 in the prior period[83]. Financial Management - The company has fully recovered the funds related to the procurement of raw plasma, resolving previous financial occupation issues[33]. - The company has utilized 90,000.00 million RMB of idle raised funds to temporarily supplement working capital, which has been fully returned to the designated account[47]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[51]. - The company has not reported any violations regarding external guarantees during the reporting period[48]. Investment and Procurement - The top five suppliers accounted for 51.41% of the total annual procurement amount, with the largest supplier contributing CNY 79.476 million, representing 40.35%[32]. - The top five customers contributed 10.84% of the total annual sales, with the largest customer accounting for CNY 17.435 million, or 2.79%[32].